Navigation Links
BioCryst Provides Update Regarding Peramivir for Influenza
Date:9/30/2009

am P. Sheridan, Chief Medical Officer at BioCryst. "The need for such studies is clear; there are currently no anti-viral agents approved for this seriously ill patient population, and no intravenous or injectable forms of any anti-viral agent are approved for any influenza indication."

One Phase 3 study is a multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of i.v. peramivir administered once-daily for five days in addition to standard of care (SOC), compared to standard of care alone, in adults and adolescents who are hospitalized due to serious influenza. The other Phase 3 study is an open-label, randomized study of the anti-viral activity, safety and tolerability of i.v. peramivir 600 mg administered once-daily compared with split doses twice-daily for five days in adult and adolescent hospitalized subjects with confirmed or suspected influenza infection. The combined enrollment target for these studies is approximately 700 patients. Further details regarding these Phase 3 study designs are available at clinicaltrials.gov at this link:

http://www.clinicaltrials.gov/ct2/results?term=Peramivir+HHS+Phase+3&recr=Open

About peramivir

Peramivir is an anti-viral agent that was discovered by BioCryst which inhibits the interactions of influenza neuraminidase, an enzyme which is critical to the spread of influenza within a host. In laboratory tests, peramivir has shown activity against pandemic H1N1 swine flu origin viral strains. Peramivir has been studied in patients with complicated and uncomplicated influenza. BioCryst's partner, Shionogi & Co., Ltd. is currently preparing to file for regulatory approval in Japan this year.

About Influenza

Influenza (the flu) is a contagious respiratory illness caused by

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
2. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
3. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
4. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
5. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
6. BioCryst Updates Peramivir Clinical Development Plan
7. BioCryst Provides Forodesine HCl Update
8. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
9. New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
10. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
11. Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... SEATTLE , BERKELEY, Kalifornien, und KOPENHAGEN, ... CMC Biologics, Inc. , ein Weltmarktführer der ... und anderen therapeutischen Proteinen, gab heute bekannt, ... Expansionsstrategie der Produktionskapazität den Ausbau der nordamerikanischen ... , mit der Ergänzung  einer Einweg-Anlage Bioreactor ...
(Date:6/30/2015)... 2015  Marken, the leading clinical trial logistics organization ... has been granted permission by the government to deliver ... product in Korea.  This precedent-setting shipment has allowed several ... continue receiving their clinical trial drugs during the outbreak ... emergency was caused by recent partial closures of medical ...
(Date:6/30/2015)... PharmaVentures is pleased to announce ... Oy (CMT) on its divestment of certain assets to ... world leading capabilities in cellular imaging and analysis. ... of successful global deals in the life science research ... Walton , CEO, PharmaVentures, commented: "PharmaVentures is delighted to ...
Breaking Medicine Technology:CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3Marken Delivers Direct To Patients During MERS Outbreak 2Marken Delivers Direct To Patients During MERS Outbreak 3PharmaVentures Completes M&A Deal for Technology in the Stem Cell & Regenerative Medicine Sector 2
... WORTH, Texas, Aug. 26 Healthpoint today announced,that ... the effectiveness of a,widely prescribed enzymatic debriding agent ... study was prompted, in part, by clinical reports,of ... healing,properties associated with Collagenase SANTYL(R) Ointment.(1,2), "Given ...
... Inc.,(Nasdaq: XTNT ) today announced that the positive ... in the most recent issue of the,peer-reviewed journal, EuroIntervention. ... Stella, M.D., of University Medical Center Utrecht, Utrecht,The Netherlands ... clinical,sites across Europe., The one-year CUSTOM II trial, ...
Cached Medicine Technology:Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 2Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4
(Date:6/30/2015)... ... 30, 2015 , ... According to a June 15th report from ... how sensory stimuli can be used to “decrease children’s anxiety and negative responses during ... autism, will compare patient experience in a “typical dental environment” with one that provides ...
(Date:6/30/2015)... ... June 30, 2015 , ... Broadway by the Sea posted its newest ... family member testimonials. Medicare rated the care center as a five-star location based on ... to give future patients a firsthand look at the facility’s satisfied residents. , ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... buying eyeglasses online , finally its here, http://www.express-glasses.com is ... shipping rates, for many location, ask about shipping with DHL Express when calling ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... currently pending in a federal multidistrict litigation now underway in the U.S. District ... next monthly Status Conference. According to the Court’s calendar, that conference has now ...
(Date:6/30/2015)... ... June 30, 2015 , ... Rocky Mountain Oils, a leading non-MLM supplier ... added a new CEO, Mr. Darold Francis. The changes will help enhance the company’s ... that customers have come to know and respect for over eight years. , “I ...
Breaking Medicine News(10 mins):Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3Health News:Broadway by the Sea Video Promotes Top Quality Service 2Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2
... A Doppler ultrasound is capable of detecting anemia in ... in the middle cerebral artery. This test is considered// ... believe that these tests can be used instead of ... from the University Medical Center in the Netherlands conducted ...
... technique -- intrauterine insemination with controlled ovarian hyperstimulation – is ... way, for some couples. ,The results of the ... ,The research was conducted on 253 couples with unexplained infertility ... were cases where no obvious abnormalities were found. ...
... Researchers at the German Naval Institute have found that scuba ... which is contrary to some reports.// ,The study ... a comparison 'control' group of 122 military submariners, all of ... published in the July 2006 issue of the Journal Chest. ...
... Group of Eight (G8) industrialised nations summit, which begins ... the global health issues high on its list// of ... officer, addressing the press stated that the G8 members ... basic guidelines for combating infectious diseases worldwide. He explained ...
... moderate amount of weight after menopause could increase the risk of ... Brigham, and Women's Hospital studied over 87,000 women, aged 30 to ... 18 was recorded and noted how it had changed since, reported ... the women who went through menopause during the course of the ...
... the highest cancer incidences rate compared to that of the ... Cancer Registry Programme (NCRP) has shown.// ,Mizoram capital ... figure of Bhopal which had witnessed a horrible gas tragedy ... told a medical conference here today., ,Nagaland and Manipur ...
Cached Medicine News:
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: